Teva agrees SPA for third Phase III MS laquinimod trial
13:20 EDT 9 Aug 2012 | SCRIP
Teva Pharmaceutical Industries and Active Biotech are to going ahead with a third Phase III trial of the oral multiple sclerosis drug candidate, laquinimod, after reaching written agreement with the US FDA on a special protocol assessment.....
Original Article: Teva agrees SPA for third Phase III MS laquinimod trial
More From BioPortfolio on "Teva agrees SPA for third Phase III MS laquinimod trial"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
